Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy

The FDA has approved Pfizer’s Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer following induction treatment.¹

The decision, based on data from the randomized Phase 3 PATINA trial, marks the first regulatory clearance for a cyclin-dependent kinase 4 and 6 inhibitor in this patient population and positions Ibrance as the only agent in its drug class indicated for HR-positive metastatic breast cancer (MBC) regardless of HER2 status.

For the biopharma industry, the approval broadens the commercial addressable population for a product that has already been prescribed to more than 900,000 patients across more than 100 countries since its initial FDA clearance in 2015. Pfizer (NYSE: PFE) gains an expanded label that extends Ibrance’s utility into a molecularly distinct breast cancer subtype that had previously lacked a dedicated maintenance regimen backed by Phase 3 evidence.

What Did the PATINA Trial Find and How Was It Designed?

The PATINA trial (AFT-38) was a randomized, open-label, global Phase 3 study sponsored by Alliance Foundation Trials in academic collaboration with six international research groups across the United States, France, Germany, Italy, Spain, Portugal, Australia, and New Zealand, with funding support from Pfizer. Patients enrolled had HR-positive, HER2-positive MBC and had not experienced disease progression after completing four to eight cycles of trastuzumab-based induction chemotherapy.

Following a median of six induction cycles, 518 patients were randomly assigned in a 1:1 ratio to receive Ibrance added to anti-HER2 and endocrine therapy (n=261) or anti-HER2 and endocrine therapy alone (n=257). The primary endpoint was investigator-assessed progression-free survival (PFS).

At a median follow-up of 53.5 months, patients receiving Ibrance achieved a median PFS of 44.3 months compared with 29.1 months in the control arm, representing a hazard ratio of 0.75 (95% CI, 0.59–0.96; P=.02).⁴ Overall survival (OS) data were not yet mature at the time of the primary analysis.

"Resistance to dual anti-HER2 and endocrine therapy remains a central clinical challenge for patients with HR-positive, HER2-positive [MBC]—even after an excellent response to initial treatment," said Otto Metzger, M.D., principal investigator of the trial for Alliance Foundation Trials and a medical oncologist at Dana-Farber Cancer Institute, in a press release. "Based on the results from the PATINA study, the addition of Ibrance in the maintenance phase can meaningfully extend the time patients go without their disease progressing. This approval gives oncologists a new, evidence-based option to optimize maintenance therapy for their patients with HR-positive, HER2-positive disease."

Why Is Resistance to Standard Therapy Such a Persistent Problem in This Breast Cancer Subtype?

HR-positive, HER2-positive breast cancer accounts for approximately 10% of all breast cancer diagnoses and is sometimes referred to clinically as double-positive or triple-positive disease.¹ Despite substantial advances in treatment, resistance to both endocrine and anti-HER2 targeted therapies remains a persistent clinical challenge for patients in this subtype.

The current standard first-line approach of dual anti-HER2 therapy combined with chemotherapy, followed by HER2-targeted and endocrine maintenance, has improved outcomes materially over the past decade, yet progression during or after maintenance therapy remains common.

PATINA represents the first registrational Phase 3 study to specifically address CDK4/6 inhibition in the hormone receptor-positive, HER2-positive metastatic setting. Preclinical data had suggested that CDK4/6 inhibition might help counteract resistance mechanisms operative against both endocrine and anti-HER2 therapies, but prospective large-scale confirmation was lacking prior to this trial.

How Does Ibrance’s Mechanism Fit Into the Broader CDK4/6 Inhibitor Landscape?

Ibrance is an oral, selective inhibitor of CDK4 and CDK6, which are regulators of the cell cycle that control cellular progression.^2,3 The drug received its first FDA approval in 2015 for HR-positive, HER2-negative MBC in combination with an aromatase inhibitor, an indication supported by data from the PALOMA-2 and PALOMA-3 trials.

The current approval extends the label into HR-positive, HER2-positive disease, which is a biologically distinct population where the drug's mechanism had not previously been validated in a Phase 3 setting. Other CDK4/6 inhibitors in the class, including Kisqali (ribociclib) and Verzenio (abemaciclib), are not approved for HER2-positive indications, leaving Ibrance as the only agent with regulatory authorization spanning both HER2-negative and HER2-positive hormone receptor-positive metastatic breast cancer.

What Are the Safety Signals Oncologists and Clinical Teams Should Monitor?

The safety profile observed in PATINA was consistent with Ibrance’s established record. Neutropenia was the most frequently reported adverse reaction, occurring in 78% of Ibrance-treated patients, with Grade 3 or higher neutropenia in 61%.

Non-hematologic toxicities included diarrhea (70%), infections (64%), stomatitis (44%), and fatigue (32%), the majority of which were mild to moderate in severity. Febrile neutropenia occurred in 0.8% of patients. Serious adverse reactions were reported in 25% of patients in the Ibrance arm, with infections accounting for 8% of serious events. Fatal adverse reactions occurred in 1.2% of palbociclib-treated patients.

What Remains Unanswered After the PATINA Approval?

The primary limitation of the current dataset is the absence of mature OS data. PFS, while a validated surrogate endpoint in MBC, does not yet confirm a survival benefit from the addition of palbociclib in this setting. OS is a secondary endpoint in PATINA and results are anticipated in future analyses.

Additionally, the trial was conducted in an open-label design, which may introduce bias in investigator-assessed PFS. Results were first presented at the 2024 San Antonio Breast Cancer Symposium and subsequently published in the New England Journal of Medicine in January 2026.⁴

Sources

1. Kay C, Martinez-Peréz C, Meehan J, et al. Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncol. 2021;17(13):1665–1681.

2. IBRANCE (palbociclib) [Prescribing Information]. New York, NY: Pfizer Inc; April 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=12921

3. Weinberg RA. pRb and Control of the Cell Cycle Clock. In: Weinberg RA, ed. The Biology of Cancer. 2nd ed. New York, NY: Garland Science; 2014:275–329.

4. Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone-receptor–positive, HER2-positive advanced breast cancer. N Engl J Med. 2026;394(5):451–462. doi:10.1056/NEJMoa2511218